Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing PPG-based Blood Pressure Measurement to the Gold Standard Manometer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03810586
Recruitment Status : Not yet recruiting
First Posted : January 18, 2019
Last Update Posted : January 21, 2019
Sponsor:
Information provided by (Responsible Party):
Biobeat Technologies Ltd.

Brief Summary:
Continuous blood pressure (BP) measurement is in use today with an ambulatory, sphygmomanometer-based, device. This device, also called BP Holter, gives essential data for the clinician, allowing better hypertension (HTN) diagnosis and treatment. Alongside, the device has some substantial limitations preventing its use as a longer term BP monitoring allowing better HTN control. A new method of continuous BP monitoring, based on photo plethysmography (PPG), has been invented to ease patients' use and increase their responsiveness. This study aims to check whether the new, PPG-based method, of BP measurement can be as good as the current, gold standard, sphygmomanometer-based device.

Condition or disease Intervention/treatment Phase
Hypertension Blood Pressure Disorders Device: Non-invasive measurement of blood pressure Not Applicable

  Hide Detailed Description

Detailed Description:

HTN is a major risk factor for cerebrovascular morbidity and mortality, yet its identification can be delayed due to lack of overt symptoms, relying on BP measurements for diagnosis. Several BP monitoring techniques are used in clinics and hospitals, and there is also an outpatient method that is used for 24-hour BP monitoring, based on a sphygmomanometer. The general notion is that by using tight BP monitoring in the clinic and during the day, the health system will be able to diagnose hypertension among individuals at an early stage, including high risk patients in the community.

Ambulatory BP monitoring for a period of 24 hours is considered to be better than measurements taken in a clinic setting. First, 24 hours monitoring performed at home can help confirm that hypertension actually does exist, thus ruling out the potential of "white coat syndrome". Second, measurements of BP during sleep also have a predictive value for hypertension in high risk patients. Furthermore, ambulatory BP measurements are a stronger predictor of all-cause and cardiovascular mortality than BP measurements in the clinic. Finally, continuous BP monitoring is beneficial for controlling hypertension in diagnosed and treated patients.

The gold standard ambulatory non-invasive BP monitor that is in broad use today is a sphygmomanometer-based device that includes a cuff, which contracts around the patient's arm and measures BP every 15 to 20 minutes. The cuff is usually uncomfortable for the patients and could prevent them from doing their everyday activities. It can also disrupt the quality of their sleep at night. For these reasons patients are sometimes reluctant to use it. A more comfortable, user- friendly device, which allows a non-invasive, continuous BP measurement will provide a simple, more efficient way for BP monitoring, and will potentially enable to improve the outcome of medical treatment.

A new way for continuous non-invasive BP monitoring is based on the reflective photo plethysmography (PPG) method. A company called "Biobeat" invented a device that measures PPG wave in high temporal resolution that maintains more properties and markings of the original pulse wave than usual PPG-based devices, thereby enabling to provide data on several physiological parameters other than Heart Rate (HR) and blood oxygen saturation, such as: Systolic Blood Pressure (SBP) and its variation, Diastolic Blood Pressure (DBP) and its variation, Pulse Pressure and more. This device can also send and surveillance. The Biobeat device (BB-613) includes either a wearable watch or a patch with a sticker that the patient puts on his/her body. This device may increase the patient's willingness to use it and can also make the measurement more reliable (explanation on the PPG-based sensor and the device itself are provided in the appendixes).

The measurements are transferred via Wi-Fi to the patient's doctor and allows close monitoring.

The purpose of the study The study's main purpose is to compare continuous 24-hour BP measurement using the non-invasive PPG-based BB-613 device with one of the gold standard sphygmomanometer-based devices that is currently-used throughout the Israeli health system (HUGECARE NIBP Monitor). As accepted according to the AAMI (Association for the Advancement of Medical Instrumentation) and the European Hypertension Society, the parameters that are investigated in this study will be systolic BP, diastolic BP and the average between them (MAP).

The use of the PPG sensor for BP measurement will be considered as successful if there will be correlation of at least 5/10/15 mmHg between the measurements of both the PPG sensor and the sphygmomanometer-based Holter. The difference between measurements of the PPG and manometer devices will be less than 5 mmHg in at least 75% of the measurements, less than 10 mmHg in at least 90% of the measurements and less than 15 mmHg in at least 96% of the measurements. The results will fulfil at least two of these criteria.

In addition to the BP measurement comparison, in this study the investigators will also compare the degree of comfort and accessibility for participants between the Bio Beat device and the gold standard Holter device that is currently in use.

Study hypothesis The study's hypothesis is that the PPG-based sensor will give reliable results of continuous BP monitoring in a comfortable and user-friendly way. In addition, the accuracy of the sensor will not be inferior to the Holter that is now in use.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Recruitment will be via printed advertisements distributed throughout the medical center. Volunteers will arrive on the morning of the test and fill a questionnaire about their demographics and every day activities. After completing the questionnaire, the participants will be connected to both devices, one on each arm and undergo a briefing about both devices. A first calibration measurement will take place followed by BP measurement every 20 minutes, and up to a 24 hour period. After 24 hours of measurements, the participants will return to Hadassah Medical Center and fill in another questionnaire, which will include feedback on the use of both devices.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Comparison of Continuous Blood Pressure Measurement Using a Non-invasive Photo Plethysmography-based Monitor With the Gold Standard Sphygmomanometer-based Holter Monitor
Estimated Study Start Date : February 2019
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Comparing blood pressure measurement
In each volunteer, non-invasive measurements of blood pressure will be taken at the same time using a holter manometry device (HUGECARE NIBP Monitor) and the Biobeat BB-613 device, and compared, to show the accuracy and the comparability of the BB-613. As mentioned in the protocol, there would be no medical interventions within the scope of this study. In case hypertension will be observed in a volunteer, the volunteer will be advised by the investigators to see his physician for further evaluation.
Device: Non-invasive measurement of blood pressure
Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)




Primary Outcome Measures :
  1. Accurate and comparable blood pressure measurement by BB-613 [ Time Frame: 24 hours per participant ]
    Blood pressure measurements using the PPG-based BB-613 device will be taken and compared to blood pressure measurements taken at the same time using the holter device HUGECARE NIBP Monitor, with the aim of showing they are comparable



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Either healthy or chronically ill who are treated accordingly and with no need of any medical intervention during the study.

Exclusion Criteria:

  • A volunteer's refusal to enter the study.
  • Patients who are currently in hospitalization or in medical assessment.
  • Pregnant women and children under 18.
  • Volunteers with powerless jurisdiction.
  • Workers of the Hadassah Medical Center

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03810586


Contacts
Layout table for location contacts
Contact: Arik Eisenkraft, MD, MHA +972-52-9210896 dr.arik@bio-beat.com
Contact: Arik Ben-Ishay +972-53-5287768 arik@bio-beat.com

Locations
Layout table for location information
Israel
The Hadassah Ein Kerem Medical Center Not yet recruiting
Jerusalem, Israel
Contact: Dean Nachman, MD    +972502217665    dean@hadassah.org.il   
Contact: Adi Gilan    +972543039545    gilanadi@gmail.com   
Sponsors and Collaborators
Biobeat Technologies Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Dean Nachman, MD The Hadassah Ein Kerem Medical Center, Jerusalem

Layout table for additonal information
Responsible Party: Biobeat Technologies Ltd.
ClinicalTrials.gov Identifier: NCT03810586     History of Changes
Other Study ID Numbers: Biobeat002
First Posted: January 18, 2019    Key Record Dates
Last Update Posted: January 21, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Biobeat Technologies Ltd.:
Hypertension
Continuous Monitoring
Non-invasive Blood Pressure
Non-invasive Monitoring

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases